SEGMENT RESULTS - Schedule of Disaggregation of Revenues (Details) - USD ($)	3 Months Ended		6 Months Ended
	Jun. 30, 2023	Jun. 30, 2022	Jun. 30, 2023	Jun. 30, 2022
Disaggregation of Revenue
TOTAL REVENUES, NET	$ 546,852,000	$ 569,114,000	$ 1,062,119,000	$ 1,221,373,000
Product line revenue reporting threshold	$ 25,000,000			$ 25,000,000
Other Sterile Injectables | Revenue from Contract with Customer Benchmark | Product Concentration Risk
Disaggregation of Revenue
Concentration risk, percentage	5.00%
Novax Inc. | Revenue from Contract with Customer Benchmark | Product Concentration Risk
Disaggregation of Revenue
Concentration risk, percentage	6.00%
Varenicline Tablets | Revenue from Contract with Customer Benchmark | Product Concentration Risk | Maximum
Disaggregation of Revenue
Concentration risk, percentage	10.00%	13.00%	13.00%	12.00%
Dexlansoprazole | Revenue from Contract with Customer Benchmark | Product Concentration Risk
Disaggregation of Revenue
Concentration risk, percentage			5.00%
Branded Pharmaceuticals
Disaggregation of Revenue
TOTAL REVENUES, NET	$ 212,377,000	$ 218,952,000	$ 409,950,000	$ 423,813,000
Branded Pharmaceuticals | Specialty Products
Disaggregation of Revenue
TOTAL REVENUES, NET	165,353,000	163,863,000	307,534,000	312,921,000
Branded Pharmaceuticals | XIAFLEX®
Disaggregation of Revenue
TOTAL REVENUES, NET	117,291,000	120,878,000	214,201,000	220,362,000
Branded Pharmaceuticals | SUPPRELIN® LA
Disaggregation of Revenue
TOTAL REVENUES, NET	28,223,000	24,739,000	51,800,000	53,569,000
Branded Pharmaceuticals | Other Specialty
Disaggregation of Revenue
TOTAL REVENUES, NET	19,839,000	18,246,000	41,533,000	38,990,000
Branded Pharmaceuticals | Established Products
Disaggregation of Revenue
TOTAL REVENUES, NET	47,024,000	55,089,000	102,416,000	110,892,000
Branded Pharmaceuticals | PERCOCET®
Disaggregation of Revenue
TOTAL REVENUES, NET	26,445,000	26,256,000	52,501,000	52,431,000
Branded Pharmaceuticals | TESTOPEL®
Disaggregation of Revenue
TOTAL REVENUES, NET	11,600,000	10,021,000	22,589,000	18,901,000
Branded Pharmaceuticals | Other Established
Disaggregation of Revenue
TOTAL REVENUES, NET	8,979,000	18,812,000	27,326,000	39,560,000
Sterile Injectables
Disaggregation of Revenue
TOTAL REVENUES, NET	137,028,000	123,171,000	238,283,000	363,199,000
Sterile Injectables | ADRENALIN®
Disaggregation of Revenue
TOTAL REVENUES, NET	27,133,000	26,774,000	52,708,000	60,597,000
Sterile Injectables | VASOSTRICT®
Disaggregation of Revenue
TOTAL REVENUES, NET	24,419,000	35,630,000	50,370,000	191,520,000
Sterile Injectables | Other Sterile Injectables
Disaggregation of Revenue
TOTAL REVENUES, NET	85,476,000	60,767,000	135,205,000	111,082,000
Generic Pharmaceuticals
Disaggregation of Revenue
TOTAL REVENUES, NET	178,579,000	203,377,000	376,759,000	389,321,000
International Pharmaceuticals
Disaggregation of Revenue
TOTAL REVENUES, NET	$ 18,868,000	$ 23,614,000	$ 37,127,000	$ 45,040,000
International Pharmaceuticals | Revenue from Contract with Customer Benchmark | Product Concentration Risk | Maximum
Disaggregation of Revenue
Concentration risk, percentage			5.00%	5.00%